Le Lézard
Classified in: Health, Covid-19 virus
Subject: PSF

Statement from the Chief Public Health Officer of Canada on March 15, 2021


OTTAWA, ON, March 15, 2021 /CNW/ - 

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks. Through the Wellness Together Canada online portal, people of all ages across the country can access immediate, free and confidential mental health and substance use supports, 24 hours a day, seven days a week.

As of March 15th, almost 3.0 million doses of COVID-19 vaccines have been administered across Canada. Federal, provincial and territorial authorities are working closely together to monitor vaccine safety following immunization with COVID-19 vaccines. To date, no unexpected vaccine safety issues have been identified. All adverse events are subject to review. All serious events undergo a detailed investigation to determine whether or not they are related to the vaccine. Information that indicates a potential link between a vaccine and a health event is considered a safety signal, which warrants appropriate action from the regulator.

Based on data up to March 5th, there have been 1,923 reports of adverse events following immunization (AEFI) with COVID-19 vaccines; these include any medical event that occurs following immunization, but is not necessarily related to the vaccine or the immunization process. A total of 214 AEFI reports to date ? about 1 in 11,000 doses administered ? were considered serious, such as a severe allergic reaction. Health Canada is aware of reports of adverse events in Europe following immunization with the AstraZeneca COVID-19 vaccine and would like to reassure Canadians that the benefits of the vaccine continue to outweigh its risks. At this time, there is no indication that the vaccine caused these events. None of the batches of the vaccine under investigation in Europe were shipped to Canada. The Government of Canada continues to work with international regulators, including the European Medicines Agency (EMA), to determine whether there is any need to take action in Canada.

As COVID-19 activity continues in Canada, we are tracking a range of epidemiological indicators to monitor where the disease is most active, where it is spreading and how it is impacting the health of Canadians and public health, laboratory and healthcare capacity. At the same time, the Public Health Agency of Canada is providing Canadians with regular updates on COVID-19 vaccines administered, vaccination coverage and ongoing monitoring of vaccine safety across the country. The following is the latest summary on national numbers and trends, and the actions we all need to be taking to reduce infection rates, while vaccination programs expand for the protection of all Canadians. Due to reduced reporting over the weekend, national seven-day averages have not been updated in today's statement. These data are still being collected and analysed. I will provide the latest numbers during my remarks tomorrow.

Since the start of the pandemic, there have been 909,157 cases of COVID-19, including 22,463 deaths reported in Canada; these cumulative numbers tell us about the overall burden of COVID-19 illness to date. They also tell us, together with results of serological studies, that the vast majority of Canadians remain susceptible to COVID-19. As vaccination programs continue to expand across Canada, there is growing optimism that widespread and lasting immunity can be achieved through COVID-19 vaccination. We now have multiple safe and effective COVID-19 vaccines with unique advantages that are authorised for use in Canada. Recent expert analysis of the efficacy and effectiveness of COVID-19 vaccines in Canada supports that priority vaccination programs are providing strong benefits for those at highest risk of severe outcomes or exposure. These encouraging findings have created opportunities for the safe and effective adjustment of vaccination programs to protect the entire adult population within a short timeframe, while contributing to health equity.

Currently, there are 31,674 active cases across the country. Although COVID-19 activity has been levelling off nationally over several weeks, average daily case counts remain high and we are now observing a recent increase. The latest national-level data show a 7-day average of 3,052 new cases daily (Mar 5-11). While COVID-19 continues to impact people of all ages in Canada, infection rates are now highest among those aged 20-39 years of age. Circulation of COVID-19 in younger, more mobile and socially-connected adults can increase the risk of spread into high-risk populations and settings. The emergence and spread of certain SARS-CoV-2 virus variants heightens this concern. For the week of February 28 - March 6, there were on average of 104,332 tests completed daily across Canada, of which 2.9 % were positive for COVID-19. As of March 14, a total of 3,302 variants of concern have been reported across Canada, including 3,031 B.1.1.7 variants, 220 B.1.351 variants and 51 P.1 variants. With the continued increase of cases and outbreaks associated with more contagious variants, we must all remain vigilant with public health measures and individual precautions to prevent a rapid shift in trajectory of the epidemic.

Nationally, severe outcomes continue to decline. Provincial and territorial data indicate that an average of 2,056 people with COVID-19 were being treated in Canadian hospitals each day during the most recent 7-day period (Mar 5-11), including 542 of whom were being treated in intensive care units. During the same period, there were an average of 31 COVID-19-related deaths reported daily.

While vaccine programs begin to accelerate, it will be important to maintain a high degree of caution. Any easing of public health measures must be done slowly with enhanced testing, screening, and genomic analysis to detect variants of concern. In particular, there must be sufficient contact tracing capacity and supports for effective isolation, given increased transmissibility of variants of concern.

Canadians are urged to remain vigilant, continue following local public health advice, and consistently maintain individual practices that keep us and our families safer: stay home/self-isolate if you have any symptoms, think about the risks and reduce non-essential activities and outings to a minimum, avoid all non-essential travel, and maintain individual protective practices of physical distancing, hand, cough and surface hygiene and wearing a well-fitted and properly worn face mask as appropriate (including in shared spaces, indoors or outdoors, with people from outside of your immediate household).

Aiming to have the fewest interactions with the fewest number of people, for the shortest time, at the greatest distance possible, while wearing the best-fitting mask is a simple rule that we can all apply to help limit the spread of COVID-19, as vaccine programs expand to protect all Canadians. 

Canadians can also go the extra mile by sharing credible information on COVID-19 risks and prevention practices and measures to reduce COVID-19 in communities and by downloading the COVID Alert app to break the cycle of infection and help limit the spread of COVID-19. Read my backgrounder to access more COVID-19 Information and Resources on ways to reduce the risks and protect yourself and others, including information on COVID-19 vaccination.

SOURCE Public Health Agency of Canada


These press releases may also interest you

at 08:03
The American Red Cross celebrates The Church of Jesus Christ of Latter-day Saints, headquartered in Salt Lake City, for its substantial donation of $7.35 million. The gift will help purchase blood equipment and biomedical emergency vehicles and will...

at 08:00
A Canada-wide Settlement Agreement was recently reached in a class action against Cook (Canada) Inc., Cook Incorporated, and William Cook Europe APS ("Cook") related to certain inferior vena cava filter products ("IVC Filter Products") marketed and...

at 08:00
Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, announced today that the US Food and Drug...

at 08:00
Key Proteo, a pioneering proteomics diagnostics company specializing in the enhanced early detection of rare but treatable genetic disorders, today announced that it has submitted a de novo classification request to the U.S. Food and Drug...

at 08:00
Human Immunology Biosciences (HI-Biotm), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced that two abstracts have been accepted for oral presentation at the...

at 08:00
PassPort Technologies, Inc. (PPTI), based in San Diego, a clinical-stage drug and medical device development company, today announced positive interim results from the Phase 1 (Part A) clinical trial of Zolmitriptan PassPort® utilizing its...



News published on and distributed by: